148 related articles for article (PubMed ID: 30941953)
1. First-line treatment choices of Turkish medical oncologists in metastatic colorectal cancer: A survey study.
Beypinar I; Araz M; Uysal M; Yalcin S
J BUON; 2019; 24(1):68-76. PubMed ID: 30941953
[TBL] [Abstract][Full Text] [Related]
2. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
László L
Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
[TBL] [Abstract][Full Text] [Related]
3. Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie).
Huemer F; Thaler J; Piringer G; Hackl H; Pleyer L; Hufnagl C; Weiss L; Greil R
BMC Cancer; 2018 Jan; 18(1):11. PubMed ID: 29298682
[TBL] [Abstract][Full Text] [Related]
4. Impact of biomarkers and primary tumor location on the metastatic colorectal cancer first-line treatment landscape in five European countries.
Kafatos G; Banks V; Burdon P; Neasham D; Lowe KA; Anger C; Manuguid F; Trojan J
Future Oncol; 2021 Apr; 17(12):1495-1505. PubMed ID: 33464120
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Value of BRAF, PI3K, PTEN, EGFR Copy Number, Amphiregulin and Epiregulin Status in Patients with KRAS Codon 12 Wild-Type Metastatic Colorectal Cancer Receiving First-Line Chemotherapy with Anti-EGFR Therapy.
Llovet P; Sastre J; Ortega JS; Bando I; Ferrer M; García-Alfonso P; Donnay O; Carrato A; Jiménez A; Aranda E; León A; Grávalos C; Cámara JC; Feliú J; Sanchíz B; Caldés T; Díaz-Rubio E
Mol Diagn Ther; 2015 Dec; 19(6):397-408. PubMed ID: 26341080
[TBL] [Abstract][Full Text] [Related]
6. Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients.
Nakayama I; Shinozaki E; Matsushima T; Wakatsuki T; Ogura M; Ichimura T; Ozaka M; Takahari D; Suenaga M; Chin K; Mizunuma N; Yamaguchi K
BMC Cancer; 2017 Jan; 17(1):38. PubMed ID: 28068936
[TBL] [Abstract][Full Text] [Related]
7. The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab.
Demurtas L; Puzzoni M; Giampieri R; Ziranu P; Pusceddu V; Mandolesi A; Cremolini C; Masi G; Gelsomino F; Antoniotti C; Loretelli C; Meriggi F; Zaniboni A; Falcone A; Cascinu S; Scartozzi M
Br J Cancer; 2017 Jul; 117(3):315-321. PubMed ID: 28632725
[TBL] [Abstract][Full Text] [Related]
8. EGFR gene copy number predicts response to anti-EGFR treatment in RAS wild type and RAS/BRAF/PIK3CA wild type metastatic colorectal cancer.
Ålgars A; Sundström J; Lintunen M; Jokilehto T; Kytölä S; Kaare M; Vainionpää R; Orpana A; Österlund P; Ristimäki A; Carpen O; Ristamäki R
Int J Cancer; 2017 Feb; 140(4):922-929. PubMed ID: 27879995
[TBL] [Abstract][Full Text] [Related]
9. Practice variation on hospital level in the systemic treatment of metastatic colorectal cancer in The Netherlands: a population-based study.
Keikes L; Koopman M; Stuiver MM; Lemmens VEPP; van Oijen MGH; Punt CJA
Acta Oncol; 2020 Apr; 59(4):395-403. PubMed ID: 32048563
[No Abstract] [Full Text] [Related]
10. Panitumumab use in metastatic colorectal cancer and patterns of RAS testing: results from a Europe-wide physician survey and medical records review.
Han van Krieken J; Kafatos G; Bennett J; Mineur L; Tomášek J; Rouleau E; Fabian P; De Maglio G; García-Alfonso P; Aprile G; Parkar P; Downey G; Demonty G; Trojan J
BMC Cancer; 2017 Nov; 17(1):798. PubMed ID: 29183279
[TBL] [Abstract][Full Text] [Related]
11. Impact of primary tumour location and RAS/BRAF mutational status in metastatic colorectal cancer treated with first-line regimens containing oxaliplatin and bevacizumab: Prognostic factors from the AIO KRK0207 first-line and maintenance therapy trial.
Hegewisch-Becker S; Nöpel-Dünnebacke S; Hinke A; Graeven U; Reinacher-Schick A; Hertel J; Lerchenmüller CA; Killing B; Depenbusch R; Al-Batran SE; Lange T; Dietrich G; Tannapfel A; Arnold D
Eur J Cancer; 2018 Sep; 101():105-113. PubMed ID: 30036739
[TBL] [Abstract][Full Text] [Related]
12. Promising New Agents for Colorectal Cancer.
Das S; Ciombor KK; Haraldsdottir S; Goldberg RM
Curr Treat Options Oncol; 2018 May; 19(6):29. PubMed ID: 29752549
[TBL] [Abstract][Full Text] [Related]
13. Impact of the Localization of the Primary Tumor and RAS/BRAF Mutational Status on Maintenance Strategies After First-line Oxaliplatin, Fluoropyrimidine, and Bevacizumab in Metastatic Colorectal Cancer: Results From the AIO 0207 Trial.
Noepel-Duennebacke S; Arnold D; Hertel J; Tannapfel A; Hinke A; Hegewisch-Becker S; Reinacher-Schick A
Clin Colorectal Cancer; 2018 Dec; 17(4):e733-e739. PubMed ID: 30145148
[TBL] [Abstract][Full Text] [Related]
14. The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials.
Holch JW; Ricard I; Stintzing S; Modest DP; Heinemann V
Eur J Cancer; 2017 Jan; 70():87-98. PubMed ID: 27907852
[TBL] [Abstract][Full Text] [Related]
15. Colorectal Cancer: Why Does Side Matter?
Gallois C; Pernot S; Zaanan A; Taieb J
Drugs; 2018 Jun; 78(8):789-798. PubMed ID: 29790124
[TBL] [Abstract][Full Text] [Related]
16. Effect of Primary Tumor Location on Second- or Later-line Treatment Outcomes in Patients With RAS Wild-type Metastatic Colorectal Cancer and All Treatment Lines in Patients With RAS Mutations in Four Randomized Panitumumab Studies.
Boeckx N; Koukakis R; Op de Beeck K; Rolfo C; Van Camp G; Siena S; Tabernero J; Douillard JY; André T; Peeters M
Clin Colorectal Cancer; 2018 Sep; 17(3):170-178.e3. PubMed ID: 29627309
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Impact of Primary Tumor Location on Clinical Outcomes of Metastatic Colorectal Cancer Treated With Cetuximab Plus Oxaliplatin-Based Chemotherapy: A Subgroup Analysis of the JACCRO CC-05/06 Trials.
Sunakawa Y; Ichikawa W; Tsuji A; Denda T; Segawa Y; Negoro Y; Shimada K; Kochi M; Nakamura M; Kotaka M; Tanioka H; Takagane A; Tani S; Yamaguchi T; Watanabe T; Takeuchi M; Fujii M; Nakajima T
Clin Colorectal Cancer; 2017 Sep; 16(3):e171-e180. PubMed ID: 27856123
[TBL] [Abstract][Full Text] [Related]
18. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.
Tol J; Punt CJ
Clin Ther; 2010 Mar; 32(3):437-53. PubMed ID: 20399983
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Guideline Adherence in Colorectal Cancer Treatment in The Netherlands: A Survey Among Medical Oncologists by the Dutch Colorectal Cancer Group.
Keikes L; van Oijen MGH; Lemmens VEPP; Koopman M; Punt CJA
Clin Colorectal Cancer; 2018 Mar; 17(1):58-64. PubMed ID: 29157662
[TBL] [Abstract][Full Text] [Related]
20. RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients.
Yao J; Zang W; Ge Y; Weygant N; Yu P; Li L; Rao G; Jiang Z; Yan R; He L; Yu Y; Jin M; Cheng G; An G
Can J Gastroenterol Hepatol; 2018; 2018():4248971. PubMed ID: 29707525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]